Vitamin A pushes breast cancer to form blood vessel cells
Contact: Karen Mallet
Georgetown University Medical Center
Washington, DC – Researchers at Georgetown University Medical Center have discovered that vitamin A, when applied to breast cancer cells, turns on genes that can push stem cells embedded in a tumor to morph into endothelial cells. These cells can then build blood vessels to link up to the body's blood supply, promoting further tumor growth.
They say their findings, published in the July 16 online issue of PLoS ONE, is a proof of principle of the new – and controversial – "vasculogenic mimicry" theory, proposing that, as needed, tumors build their own blood pipelines. This is very different from the well-accepted role of tumor angiogenesis, when tumors send signals to blood vessels to grow toward the cancer.
The study's senior author, Stephen W. Byers, Ph.D., a professor of oncology and cell biology at Georgetown's Lombardi Comprehensive Cancer Center, also says that this study helps explain why retinoids-- natural or synthetic vitamin A agents--have had mixed results in treating cancer. "Finding that vitamin A may cause some breast cancer cells to form blood vessels brings up the rather disturbing notion that treatment with these drugs may actually stimulate tumor growth," says Byers.
For example, use of beta-carotene, the most important dietary precursor of vitamin A and the chemical that makes carrots orange, has been found to increase lung cancer progression in a large clinical trial. Additionally, fenretinide, a synthetic retinoid, appears to reduce the risk of second breast cancers in premenopausal women, but increase the risk in postmenopausal women, Byers says.
"None of this means that people should avoid foods rich in vitamin A, or should refuse to take their vitamins," he says. "What led us to this study is that previous research on retinoids implied that they may be effective in a preventative setting, but may actually have a negative effect after tumor initiation and during progression."
The researchers demonstrated that treating the cells with RA turns on 81 genes that are associated with endothelial cells, such as vascular endothelial (VE) cadherin, which plays a role in binding endothelial cells together into a structure. When they then mixed the treated cancer cells with endothelial cells taken from human umbilical cord blood, structures similar to blood vessels developed within the tumor masses grown in culture.
This makes sense, says Byers, because vitamin A is known to be necessary for embryonic development precisely because it helps to "differentiate" stem cells, pushing them to become required tissue. In the same way, taking too much vitamin A can result in birth defects.
So, in cancer cells, vitamin A seems to be turning on cancer stem cells, allowing them to form the blood vessel tissue -- needed most as tumors develop. Independent formation of these vessels is what has been proposed in the vasculogenic mimicry theory, developed by Mary Hendrix, , Ph.D., of Northwestern University, Byers says.
"Like many scientists, I was not an advocate of this notion because it seemed too far fetched, but now, based on these findings and my years of working on retinoids and breast cancer, I am a believer," he says. "And what this study tells us is that treating stem cells that have retained the ability to become cell types other than breast with differentiating agents such as vitamin A may cause an inappropriate cell to develop - in this case potentially promoting tumor vasculogenesis and growth, which is not a desired effect."
While there is much work yet to do to further define the molecular mechanisms by which endothelial cells form within tumors and assemble themselves into blood vessels, Byers says that these findings open a new door to drug development. "Cancer drugs based on stopping host-derived angiogenesis have met with mixed success, and we think there could be new ways to target and halt the ability of tumor cells themselves to contribute to their own blood supply," he says.
The study was funded by grants from the National Institutes of Health and the Department of Defense. Co-authors include Georgetown University Medical Center researchers Yoshimi Endo, M.D., Ph.D., Kamla Deonauth, Ph.D., and Priya Prahalad BS, (co-first authors of the study) and Yuelin Zhu Ph.D.
About Lombardi Comprehensive Cancer Center
The Lombardi Comprehensive Cancer Center, part of Georgetown University Medical Center and Georgetown University Hospital, seeks to improve the diagnosis, treatment, and prevention of cancer through innovative basic and clinical research, patient care, community education and outreach, and the training of cancer specialists of the future. Lombardi is one of only 39 comprehensive cancer centers in the nation, as designated by the National Cancer Institute, and the only one in the Washington, DC, area. For more information, go to http://lombardi.georgetown.edu.
About Georgetown University Medical Center
Georgetown University Medical Center is an internationally recognized academic medical center with a three-part mission of research, teaching and patient care (through our partnership with MedStar Health). Our mission is carried out with a strong emphasis on public service and a dedication to the Catholic, Jesuit principle of cura personalis -- or "care of the whole person." The Medical Center includes the School of Medicine and the School of Nursing and Health Studies, both nationally ranked, the world-renowned Lombardi Comprehensive Cancer Center and the Biomedical Graduate Research Organization (BGRO), home to 60 percent of the university's sponsored research funding.
By news release
Jul 16, 2008 - 6:31:40 PM